AI Article Synopsis
Article Abstract
Introduction: The WHO estimates that 180 million people are chronically infected with hepatitis C virus (HCV) throughout the world. Despite the emergence of new therapies, the combination of pegylated interferon and ribavirin remains the accepted standard of care in low-income countries, including Mexico. Two types of peginterferon are available (peginterferon alfa-2a and peginterferon alfa-2b), and both are recommended for the treatment of HCV, although there is controversy over which treatment option is most effective.
Methodology: This was a retrospective cohort study at a infectious disease center in Mexico City. Patients were included if they had received peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin. Age, sex, body mass index, AST platelet ratio index, HCV RNA viral load, levels of alanine aminotransferase, aspartate aminotransferase, bilirubin, albumin, and hemoglobin, and platelet and leukocyte counts of the subjects were assessed before treatment and at weeks 4, 12, 24, 48, and 6 months post treatment.
Results: Eighty-seven patients met the inclusion criteria. A sustained virological response (SVR) occurred in 33 (38%) of them, 11 (33%) given peginterferon alfa-2a and 22 (67%) given peginterferon alfa-2b (p = 0.17). Seventeen patients (20%) relapsed, 7 (41%) of those given peginterferon alfa-2a and 10 (59%) of those given peginterferon alfa-2b (p = 0.76); 27 (31%) patients were non-responders (p = 0.09). The rates of anemia, thrombocytopenia, and leukopenia were similar in both groups.
Conclusions: Similar SVR rates and frequencies of adverse events were observed. Either type of interferon can be used to treat HCV infection in the Mexican population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3855/jidc.5284 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ZNF350 gene polymorphisms promote the response to Peg-IFNα therapy through JAK-STAT signaling pathway in patients with chronic hepatitis B.
Front Immunol
November 2024
Department of Laboratory Medicine, Fujian Key Laboratory of Laboratory Medicine, Gene Diagnosis Research Center, Fujian Clinical Research Center for Clinical Immunology Laboratory Test, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Background: The varying individual responses to Pegylated interferon-α (Peg-IFNα) in patients with chronic hepatitis B (CHB) pose significant hurdles in treatment optimization, and the underlying mechanisms remain unclear.
Objective: We aimed to identify genetic polymorphisms influencing the efficacy of Peg-IFNα in patients with HBeAg-positive CHB, with the goal to predict Peg-IFNα response before treatment.
Methods: We employed an Asian Screening Array analysis involving 124 HBeAg-positive CHB patients treated with Peg-IFNα.
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study.
Lancet Gastroenterol Hepatol
December 2024
Department of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Article Synopsis
- Chronic hepatitis B virus (HBV) is a significant global health concern, with existing treatments yielding low rates of HBsAg seroclearance; VIR-2218 (elebsiran) is being studied for its potential to reduce HBsAg levels.
- This phase 2 open-label study involved participants aged 18-65 from various countries who had chronic HBV but no cirrhosis, assessing the safety and effectiveness of VIR-2218 alone and in combination with pegylated interferon-alpha-2a.
- The study aimed to measure adverse events and clinical outcomes, including the reduction of HBsAg and long-term seroclearance rates among those receiving different treatment regimens over a period ranging from
Pegylated interferon-α2a in cutaneous T-cell lymphoma - a multicenter retrospective data analysis with 70 patients.
J Dtsch Dermatol Ges
November 2024
Department of Dermatology and Venereology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Article Synopsis
- Interferon-alpha is crucial for treating cutaneous T-cell lymphomas (CTCL), but the approved version (IFN-α2a) has been unavailable since January 2020, prompting the use of pegylated interferon-α2a (pegIFN-α2a), which is not officially approved for this condition.
- A study involving 70 CTCL patients from twelve German skin centers found a 55.2% overall response rate to pegIFN-α2a, with common adverse effects leading to a 50% discontinuation rate within about 63 weeks.
- The findings suggest that pegIFN-α2a therapy may have similar efficacy and side effects as the discontinued IF
CXCR7 genetic variant predicts treatment response of pegylated-interferon α in HBeAg-positive chronic hepatitis B patients.
Antiviral Res
November 2024
State Key Laboratory of Organ Failure Research, MOE Key Laboratory of Infectious Diseases Research in South China, Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Guangdong Provincial Clinical Research Center for Viral Hepatitis, Guangdong Institute of Liver Diseases, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China; The Key Laboratory of Molecular Pathology (Hepatic Diseases) of Guangxi, Department of Pathology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China. Electronic address:
Article Synopsis
- - The study investigates the role of CXC chemokine receptor 7 (CXCR7) in patients with chronic hepatitis B (CHB) undergoing pegylated interferon-alpha (PegIFNα) therapy, specifically looking at how CXCR7 can predict treatment response.
- - Researchers analyzed data from 945 Chinese CHB patients who received PegIFNα treatment and found that a specific SNP (rs2952665) within the CXCR7 gene was significantly linked to successful treatment outcomes.
- - The study concludes that CXCR7_rs2952665, alongside a polygenic score combining it with other known SNPs, serves as a strong predictor for treatment efficiency in HBeAg-positive CHB patients.
Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera.
Blood Adv
October 2024
Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
Article Synopsis
- The COMBI II clinical trial evaluated the safety and efficacy of combining ruxolitinib and low-dose pegylated interferon alfa-2a in 25 patients with newly diagnosed polycythemia vera (PV) over two years.
- The results showed a high peripheral blood cell count remission rate of 92% and 56% of patients meeting remission criteria, with notable improvements in symptoms like abdominal discomfort and night sweats.
- Additionally, the treatment significantly decreased the JAK2V617F variant allele frequency, with 60% of patients achieving molecular remission, indicating effective outcomes with manageable toxicity.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!